PharmaCorp Rx Inc. has seen notable movement in its stock performance this week, reflecting broader trends in the pharmaceutical sector.
PharmaCorp Rx Inc. (PCRX.V) experienced a slight uptick in stock price on Friday, closing at C$0.41, which represents a 1.22% increase for the day. However, the stock has faced challenges over the past week, declining by 9.78%. This performance adds to a year-to-date decrease of 13.54%, raising questions about the company's current standing in the market.
Investor takeaway: With a market cap of approximately C$81.7 million and a bearish outlook reflected in its recent stock performance, investors may want to consider the broader context of PharmaCorp Rx's financial health and market dynamics.
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$79.78M
52W high
$0.58
52W low
$0.38
1W change
-3.57%
Beta
-3.95
Analyst Price Targets
Based on analyst covering PCRX · as of Sep 17, 2026
Wall Street analysts forecast PCRX stock price to rise 64.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.67
+64.6% Upside
Current Price
C$0.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
43.8%
Annualized
90-Day Vol
51.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.44 |
| 60 trading days | C$0.36 | C$0.29 – C$0.45 |
| 90 trading days | C$0.34 | C$0.26 – C$0.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
PharmaCorp Rx Inc. Stock Shows Mixed Signals Amidst Market Volatility
With a beta of -4.29, PharmaCorp's stock is significantly less volatile than the broader market, which may appeal to conservative investors seeking stability amidst uncertainty.
Bull case
Analysts are optimistic about PharmaCorp, with an average target price of C$0.67, suggesting a potential upside of 62.6%. This positive outlook may come from expected growth in the pharmaceutical sector, even with current challenges.
Bear case
The company is facing financial difficulties, reflected in its negative profit margin of -3.9% and a return on equity (ROE) of -2.5%. These factors could deter potential investors. Additionally, the stock has consistently traded below its moving averages, indicating bearish sentiment.
Weekly Price Action
PharmaCorp Rx Inc. (PCRX.V) closed at C$0.41 on Friday, reflecting a modest increase of 1.22% for the day. However, over the course of the week, the stock has decreased by 9.78%, contributing to a year-to-date decline of 13.54%. This mixed performance highlights the volatility that the stock has experienced recently.
Technical Picture
The technical indicators for PharmaCorp Rx Inc. reveal that the stock is currently trading below both its 50-day moving average (C$0.49) and 200-day moving average (C$0.47), with the current price representing a 16.5% and 12.1% discount to these averages, respectively. The stock has a 52-week trading range of C$0.40 to C$0.58, indicating it is currently near the lower end of this range. With a beta of -4.29, the stock is less volatile compared to the market, which may appeal to risk-averse investors. The latest trading volume of 109,365 shares is notably above the 20-day average of 71,299 shares, suggesting increased interest from investors.
Insider Activity
No recent insider activity has been reported for PharmaCorp Rx Inc., which may indicate a lack of confidence or significant developments within the company from its leadership.
Analyst Outlook
Despite the recent downturn, analysts remain bullish on PharmaCorp Rx Inc., with an average target price of C$0.67, suggesting an implied upside of 62.6%. This optimistic outlook may be based on anticipated growth in the pharmaceutical sector, although investors should weigh this against the company's current financial challenges.
Price Action Summary
PharmaCorp Rx Inc. (PCRX.V) closed at C$0.41, reflecting a 1.22% increase for the day, but a significant 9.78% decline over the week. Investors should consider both the bullish analyst targets and the underlying financial metrics as they assess the stock's potential.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
